Get the Stockscreener App
2.16
0.00%
0.00
After Hours:
2.18
0.02
+0.93%
Rani Therapeutics Holdings Inc stock is traded at $2.16, with a volume of 48,725.
It is up +0.00% in the last 24 hours and down -32.50% over the past month.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.
See More
Previous Close:
$2.16
Open:
$2.11
24h Volume:
48,725
Relative Volume:
0.89
Market Cap:
$62.83M
Revenue:
$3.04M
Net Income/Loss:
$-33.97M
P/E Ratio:
-1.5652
EPS:
-1.38
Net Cash Flow:
$-52.47M
1W Performance:
-0.92%
1M Performance:
-32.50%
6M Performance:
-30.55%
1Y Performance:
-0.69%
1-Day Range:
$2.1042
$2.18
1-Week Range:
$2.00
$2.2952
52-Week Range:
$1.82
$8.75
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Name
Rani Therapeutics Holdings Inc
Sector
Industry
Phone
(408) 457-3700
Address
2051 RINGWOOD AVENUE, SAN JOSE
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jul-27-22 | Initiated | H.C. Wainwright | Buy |
| Jun-13-22 | Initiated | Wedbush | Outperform |
Rani Therapeutics Holdings Inc Stock (RANI) Latest News
Ragnar Metals Uncovers High-Value Rare Earths - TipRanks
Rambus Inc. (RMBS): Hedge Funds Are Bearish On This Affordable Stock Under $40 - Yahoo Finance
Ameritas Investment Partners Inc. Has $1.98 Million Stock Holdings in Rambus Inc. (NASDAQ:RMBS) - Defense World
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 YearsBristol-Myers Squibb (NYSE:BMY) - Benzinga
Will 'Game Changer' Antipsychotic Live Up to the Hype? - Medscape
Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary - Pharmaceutical Technology
Skin deep: Organon buys Dermavant for $1.2B - BioWorld Online
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B - Benzinga
Organon to buy Roivant's dermatology unit for up to $1.2 billion - XM
Rani Therapeutics appoints Marcum as new auditor - Investing.com India
Rani Therapeutics appoints Marcum as new auditor By Investing.com - Investing.com Canada
Rani Therapeutics appoints Marcum as new auditor By Investing.com - Investing.com UK
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of “Buy” by Analysts - Defense World
Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) market cap dropped US$17m last week; Retail investors bore the brunt - Simply Wall St
Rani Therapeutics to Participate in September Investor Conferences - ForexTV.com
Rani Therapeutics to Participate in September Investor Conferences - GlobeNewswire
Rani Therapeutics to Participate in September Investor Conferences - StockTitan
Rani Therapeutics to Participate in September Investor Conferences - Yahoo Finance
Vanguard Group Inc. Has $2.13 Million Holdings in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) - Defense World
Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders are individual investors who were rewarded as market cap surged US$12m last week - Yahoo Finance
RANIRani Therapeutics Holdings, Inc. Latest Stock News & Market Updates - StockTitan
Rani Therapeutics (NASDAQ:RANI) PT Lowered to $9.00 - Defense World
Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Price Target at $12.38 - MarketBeat
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Rating of “Buy” from Analysts - Defense World
Rani Therapeutics (NASDAQ:RANI) Given New $9.00 Price Target at HC Wainwright - MarketBeat
Rani Therapeutics stock target cut, rating held on Q2 results By Investing.com - Investing.com Canada
Rani Therapeutics price target lowered to $9 from $13 at H.C. Wainwright - TipRanks
FY2024 EPS Estimates for Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Lowered by Analyst - MarketBeat
Brokers Set Expectations for Rani Therapeutics Holdings, Inc.’s FY2024 Earnings (NASDAQ:RANI) - Defense World
FY2024 EPS Estimates for Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Reduced by Analyst - Defense World
How To Buy Rani Therapeutics Holdings, Inc. Stock Online in August 2024 - Traders Union
Rani Therapeutics (NASDAQ:RANI) Announces Quarterly Earnings Results - MarketBeat
Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update - GlobeNewswire
Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update - StockTitan
Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update - Yahoo Finance
Rani Therapeutics (NASDAQ:RANI) Coverage Initiated at Oppenheimer - Defense World
Rani Therapeutics (NASDAQ:RANI) Receives New Coverage from Analysts at Oppenheimer - MarketBeat
Rani Therapeutics initiated with an Outperform at Oppenheimer - TipRanks
Rani Therapeutics to Participate in August Investor Conferences - GlobeNewswire
Rani Therapeutics to Participate in August Investor Conferences - StockTitan
Rani Therapeutics to Participate in August Investor Conferences - Yahoo Finance
Rani Therapeutics secures $10 million in stock sale - Investing.com India
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Recommendation of “Buy” from Analysts - Defense World
Form 424B5 Rani Therapeutics Holdin - StreetInsider.com
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $12.29 Consensus Target Price from Analysts - MarketBeat
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering - ForexTV.com
Rani Therapeutics secures $10 million in stock sale By Investing.com - Investing.com UK
Rani Therapeutics prices securities offering to raise $10 million - Seeking Alpha
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering - GlobeNewswire
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering - StockTitan
Rani Therapeutics Holdings Inc Stock (RANI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):